Pegvisomant
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pegvisomant |
| DrugBank ID | DB00082 |
| Brand Names (EU) | Somavert |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.63% |
Approved Indication (EMA)
Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated. Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF -I concentrations or was not tolerated.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | borderline ovarian serous tumor | 98.63% | DL |
| 2 | rete ovarii cystadenoma | 98.60% | DL |
| 3 | ovarian papillary cystadenoma | 98.60% | DL |
| 4 | pyelonephritis | 98.57% | DL |
| 5 | malignant ovarian Brenner tumor | 98.56% | DL |
| 6 | aleukemic mast cell leukemia | 98.56% | DL |
| 7 | ovarian mucinous cystadenofibroma | 98.54% | DL |
| 8 | ovarian benign neoplasm | 98.54% | DL |
| 9 | mucinous ovarian cystadenoma | 98.53% | DL |
| 10 | ovarian surface papilloma | 98.51% | DL |
| 11 | serous neoplasm | 98.47% | DL |
| 12 | mucinous ovarian cancer | 98.18% | DL |
| 13 | ovarian clear cell cancer | 97.95% | DL |
| 14 | mucosal melanoma | 97.74% | DL |
| 15 | benign shuddering attacks | 97.58% | DL |
| 16 | extrapyramidal and movement disease | 97.58% | DL |
| 17 | chronic tic disorder | 97.45% | DL |
| 18 | psychogenic movement disorders | 97.44% | DL |
| 19 | ovarian germ cell tumor | 97.34% | DL |
| 20 | primary orthostatic tremor | 97.30% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.